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Cardiovascular Responses of Untrained and Endurance-Trained Dogs to 
Oscillatory Blood Volume Shifts (funded by AFOSR)
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 Apollo: 12 flights (9 lunar), 31 men (5 
twice), 6-13 days
 Demonstrated operational proficiency,  
recovery in implementing Apollo
 Decreased postflight orthostatic 
tolerance
 Post flight dehydration, weight loss
 Reduced post flight exercise 
tolerance
 Apollo 15 cardiac arrhythmia
 Decreased RBC mass, plasma 
volume
 Mercury: 6 flights, 6 men, 15 minutes-34 hours
 Demonstrated basic survivability, functionality
 Gemini: 10 flights, 16 men (4 twice), 5 hours-14 days
 Demonstrated operational proficiency,  recovery in preparation for Apollo
 Moderate post flight orthostatic intolerance
 Moderate post flight loss of exercise capacity
 Moderate RBC mass loss
 CVD during flight appeared adaptive, 
stabilized after 4-6 weeks, did not impair 
health or performance
 LBNP reliably predicted post flight CV 
status, recovery associated with amount 
of personal exercise
 No significant inflight decrement in work 
capacity, physiological responses to 
exercise
 Cardiac electrical activity by VCG not 
significantly altered, WNL
 Single episode of significant 
arrhythmia during exercise in one 
crewman early in flight
 Decreased CO post flight, due to reduced 
venous return
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Increased risk of orthostatic intolerance
• Seated upright—parallel to G direction
• G load lower but lasted longer
Implication
• Fainting (GLOC) during piloting and landing
• Inability to execute emergency egress after 
landing
Pre-
Challenger
Post-
Challenger
Pre-egress
% missions 25% 54%
% crewpersons 6% 13%
In clinic
% missions 13% 39%
% crewpersons 3% 10%
Number of missions 24 13
Average mission duration 6 5.5
STS-4   51-L (25) STS-26   135 
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E294, CV Adaptation – Blomqvist
E066, In-flight Study of CV 
Deconditioning – Farhi
E022, Autonomic CV Control –
Eckberg
E198, Pulmonary Function – West
E192, Fluid-Electrolyte Regulation 
– Leach
E261, Erythrokinetics – Alfrey
E141, Blood Volume - Alfrey
Human Biomedical Experiments
Spacelab Life Sciences 1, 2
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Follow-on to Skylab

407, Photography of 
Body Fluid Shift
412, Treadmill 
Operation
415, Tissue Pressure 
Tonometry
416, Ambulatory 
Monitoring
423, In-flight Fluid 
Changes
441, BP Monitoring 
during Re-entry
446, Leg 
Plethysmography
453, Combined Blood 
Investigations
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 Extended Duration Orbiter Project
 1988: Congress allocated $125M to extend STS from ~10 days maximum up to 
16 days, potentially up to 30 days
 1992-2003: 14 EDO flights, 14-18 days
 Concerns
 Astronaut Office
o Unaided egress
o Manual landing proficiency
 Space Life Sciences
o Cardiovascular (orthostatic intolerance)
o Neuromuscular (input/output offset using hand controllers; post flight 
disequilibrium)
o Neurosensory (vertigo)
o Musculoskeletal (exercise capacity re: unassisted ambulation in 34-kg LES)
 Extended Duration Orbiter Medical Project
 Dec. 1989-Sep. 1995: $40M
 NASA civil service lead scientists, academic participants
 Implementation via Detailed Supplementary Objectives (DSO)
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625
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331, LES & Locomotion
402, CVD c/m
463, In-flight Holter
466, Pre/Post CV Assessment
470, TCD, Trans-Cranial Doppler
476, In-flight Aerobic Ex
478 & E140, In-flight LBNP 
479, Hyperosmotic Fluid C/M
480, Heavy Water
482, Cardiac Rhythm Diturbances
601, Baroreceptor Function
602, BP Variability
603A/B/C, Re-entry Monitoring
604, Visual Vestib Integr & Adapt
605, Postural Equilibrium Control
607, LBNP Following Spaceflight
608, Aerobic & Anaerobic Metab
613, Endocrine Regulation
614, Head & Gaze Stability
618, Intense Exercise
620, Seat Egress Ability
621, In-flight Use of Florinef
623, LBNP C/M Trial
625, Blood Volume
626, Extended Stand Test
OST, Operational Stand Test
REAGS, Re-Entry Anti-G Suit Detailed 
Supplementary 
Objectives, DSOs
(in-house operational 
investigations)
EDOMP 
1989 - 1994
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Re-entry 
Monitoring
(DSO 603)
Lower Body 
Negative 
Pressure
(DSO 478, E140, 
DSO 623)
Heart Rate, Blood Pressure, 
G-level and Posture Before, 
During and After Entry, 
Descent, Landing and Egress
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Oral Fluid Loading during 
Lower Body Negative Pressure
 Need for effective OI countermeasures due to 
upright piloted landings of Space Shuttle
 “Combined countermeasure” 4-hr LBNP + oral 
saline fluid loading more  effective than fluid 
loading alone (Hyatt et al., 1977)
2-hr treatment shown not effective
 LBNP + fluid loading selected as Spacelab 
study (Johnson, 1978), in-flight medical 
investigation (Charles, 1989)
 NASA adopted fluid loading alone at end of 
mission as interim OI countermeasure for 
Shuttle crews (1984)

PLBNPD ≈ 230 m (770 ft) 
above sea level
PLBNPD ≈ 600 m (1970 ft) 
above sea level
ΔΡ
ΔΡ
ΔΡ
FGRF ≈ 0
FGRF ≈ 0.4 BW
FGRF ≈ BW
} Blood volume shift ≈ 0.6 lf(ΔΡ, time @ ΔΡ) 
Sources: Rowell, 1986; Buckey, 2006; Smith, 1990. 
 = Pambient - PLBNPD
“LBNP … 
provides a 
non-gravity 
dependent 
way to shift 
fluid from the 
upper to lower 
body.”
Buckey, 2006.
ΔΡ load
ΔΡ load
ΔΡ load
ΔΡ load ≈ ΔΡ x area of opening
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1. Determine efficacy of combined fluid loading 
and sustained LBNP countermeasure to 
reverse OI during space flight and to assess 
length of time countermeasure would be 
effective during space flight
2. Determine whether countermeasure can be 
successfully employed 24 h prior to landing 
to prevent OI during stand test after landing
3. Assess rate of development of OI during 
short-duration space flight using more 
frequent LBNP tests than Skylab
• 18 astronauts (15 men, 3 women) volunteered 
– Data combined from two separate but related 
studies (DSO 478 & 623)
– Analyses based on subsets with necessary 
characteristics
• Space Shuttle 
flights of 6-14 days
• Collapsible LBNP 
device used as 
both testing and 
countermeasure 
modality
 LBNP “ramp” tests at ~3-day intervals to document progressive 
loss of orthostatic tolerance (n=13) 
• 5-min stages of 10 mmHg decompression to 50 mmHg 
 No countermeasure prior to these ramp tests
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 Ingested ~1 ℓ water or artificially-sweetened fruit beverage and ~8 
gm salt during 4-h LBNP “soak” treatment (n=8)
 Compared pre-flight heart rate (HR) and blood pressure (BP) 
responses to prior LBNP ramp test to in-flight responses to ramp 
tests  one and two days after 4-h LBNP soak treatment
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LBNP Treatment “Soak”: 240 minutes
Salt and Water Ingestion (60 
min)
↑ … … ↓
FD 1 FD 2 FD 3 Treatment +1 +2 FD n
Legend: ↑ Launch ↓ Landing Ramp Test Soak Treatment
Flight Days
Crewmembers participated in LBNP ramp test (R) and soak 
treatment (S) sessions based on availability in flight.  Shaded 
squares indicate end of mission (R+0, landing day)
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 All crewmembers used NASA’s operational fluid-
loading protocol before de-orbit and wore AGS 
during re-entry and landing
 Countermeasure subjects performed LBNP soak 
within 24 hours of landing (n=5)
 Stand test results were compared to cohort of 
subjects from STS flights of similar duration 
(n=7)
 5/5 treatment subjects completed 5-minute post-flight 
stand test
 5/7 untreated cohort subjects completed it 
 No between-group differences in HR and BP responses 
to standing post-flight 
 4-hr LBNP plus fluid loading proved too 
cumbersome for short Shuttle missions
 Unacceptable constraint for 4 hr during busy 
pre-landing preps
 Abbreviated 2-hr treatment previously shown to 
be ineffective
 Too much time required for treating entire 
crew: 4 hours x 7 astronauts within 16-hour 
duty day
 Multiple LBNPDs?
 Triage, prioritize pilots?
 Incidence of presyncope is ~20% following 
short-duration missions
 “Treatment is worse than the disease”
 Multiple other operational 
countermeasures to OI already 
available:
 Oral fluid loading
 Recumbent seating
 Lower body compression garments
 Cooling garments
 Mission design not requiring early 
sustained orthostasis
International Space Station (ISS)
Orion MPCV 
(NASA/Lockheed-Martin)
Crew Dragon (SpaceX)
Starliner CST-100 (Boeing)
time.com/meet-the-twins-unlocking-the-secrets-of-space/

FIELD TEST FLUID SHIFTS
https://arstechnica.com/science/2017/03/for-the-first-time-nasa-has-begun-detailing-its-deep-space-exploration-plans/.

https://arstechnica.com/science/2017/03/for-the-first-time-nasa-has-begun-detailing-its-deep-space-exploration-plans/.

https://ntrs.nasa.gov/archive/nasa/casi.ntrs.nasa.gov/20150001240.pdf
 Space exploration has epitomized complex 
activities resulting in dramatic success for 
generation or more
 Progress in space exploration requires 
concerted efforts of many dedicated people over 
long periods of time to implement many complex 
activities
 Every step forward comprises multitude of 
smaller steps in technical and programmatic 
domains
 Success depends on ability to coordinate people 
in accomplishing common important goal
 University of Kentucky experience was 
foundation for long and rewarding career in 
space life sciences research and management
